These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 11257073

  • 1. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition.
    Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ.
    Circulation; 2001 Mar 20; 103(11):1488-91. PubMed ID: 11257073
    [Abstract] [Full Text] [Related]

  • 2. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE.
    Circulation; 1997 Dec 02; 96(11):3860-6. PubMed ID: 9403608
    [Abstract] [Full Text] [Related]

  • 3. Rapid platelet-function assay: an automated and quantitative cartridge-based method.
    Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS.
    Circulation; 1999 Feb 09; 99(5):620-5. PubMed ID: 9950658
    [Abstract] [Full Text] [Related]

  • 4. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Voss R.
    J Thromb Thrombolysis; 2001 Oct 09; 12(2):129-39. PubMed ID: 11729364
    [Abstract] [Full Text] [Related]

  • 5. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Oct 09; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 6. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.
    Coller BS, Lang D, Scudder LE.
    Circulation; 1997 Feb 18; 95(4):860-7. PubMed ID: 9054743
    [Abstract] [Full Text] [Related]

  • 7. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
    Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE.
    Circulation; 1998 May 05; 97(17):1680-8. PubMed ID: 9591761
    [Abstract] [Full Text] [Related]

  • 8. Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.
    Bertram U, Moser M, Peter K, Kuecherer HF, Bekeredjian R, Straub A, Nordt TK, Bode C, Ruef J.
    J Thromb Thrombolysis; 2002 Dec 05; 14(3):197-203. PubMed ID: 12913399
    [Abstract] [Full Text] [Related]

  • 9. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2003 Feb 05; 145(2):e6. PubMed ID: 12595861
    [Abstract] [Full Text] [Related]

  • 10. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54.
    Naimushin YA, Mazurov AV.
    Biochemistry (Mosc); 2005 Jul 05; 70(7):782-9. PubMed ID: 16097942
    [Abstract] [Full Text] [Related]

  • 11. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
    Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, Feuerstein GZ.
    J Pharmacol Exp Ther; 2002 Dec 05; 303(3):1114-20. PubMed ID: 12438534
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE.
    Am Heart J; 2000 Apr 05; 139(4):696-703. PubMed ID: 10740154
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L, Alves VL, Phillips DR.
    Circulation; 2003 Mar 04; 107(8):1123-8. PubMed ID: 12615789
    [Abstract] [Full Text] [Related]

  • 14. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
    Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC.
    Am Heart J; 2002 Apr 04; 143(4):602-11. PubMed ID: 11923796
    [Abstract] [Full Text] [Related]

  • 15. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 14; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 17. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.
    Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C.
    Blood; 1998 Nov 01; 92(9):3240-9. PubMed ID: 9787160
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
    Kereiakes DJ, Lorenz T, Young JJ, Kukielka G, Mueller MN, Nanniazzi-Alaimo L, Phillips DR.
    J Thromb Thrombolysis; 2001 Oct 01; 12(2):123-7. PubMed ID: 11729363
    [Abstract] [Full Text] [Related]

  • 19. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
    Peter K, Kohler B, Straub A, Ruef J, Moser M, Nordt T, Olschewski M, Ohman ME, Kübler W, Bode C.
    Circulation; 2000 Sep 26; 102(13):1490-6. PubMed ID: 11004138
    [Abstract] [Full Text] [Related]

  • 20. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
    Peter K, Straub A, Kohler B, Volkmann M, Schwarz M, Kübler W, Bode C.
    Am J Cardiol; 1999 Sep 01; 84(5):519-24. PubMed ID: 10482148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.